These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 19407498)

  • 1. Growth hormone receptor exon 3 isoforms and their implication in growth disorders and treatment.
    Jorge AA; Arnhold IJ
    Horm Res; 2009 Apr; 71 Suppl 2():55-63. PubMed ID: 19407498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency.
    Jorge AA; Marchisotti FG; Montenegro LR; Carvalho LR; Mendonca BB; Arnhold IJ
    J Clin Endocrinol Metab; 2006 Mar; 91(3):1076-80. PubMed ID: 16291702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homozygosity of the d3-growth hormone receptor polymorphism is associated with a high total effect of GH on growth and a low BMI in girls with Turner syndrome.
    Binder G; Trebar B; Baur F; Schweizer R; Ranke MB
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):567-72. PubMed ID: 17973940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of the exon 3 deleted/full-length GHR polymorphism with recombinant growth hormone dose in growth hormone-deficient adults.
    Meyer S; Schaefer S; Stolk L; Arp P; Uitterlinden AG; Plöckinger U; Stalla GK; Tuschy U; Weber MM; Weise A; Pfützner A; Kann PH
    Pharmacogenomics; 2009 Oct; 10(10):1599-608. PubMed ID: 19842933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive effect of GHRd3 and COLIA1 polymorphisms on the GH-substitution dose in GH-deficient adults.
    Hartleb S; Plöckinger U; Stalla GK; Tuschy U; Weber MM; Pfützner A; Kann PH; ;
    Pharmacogenomics; 2011 Dec; 12(12):1653-61. PubMed ID: 22026923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of serum components of the GH-IGFs-IGFBPs system with GHR-exon 3 polymorphism in normal and idiopathic short stature children.
    Ballerini MG; Domené HM; Scaglia P; Martínez A; Keselman A; Jasper HG; Ropelato MG
    Growth Horm IGF Res; 2013 Dec; 23(6):229-36. PubMed ID: 23999134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children.
    Binder G; Baur F; Schweizer R; Ranke MB
    J Clin Endocrinol Metab; 2006 Feb; 91(2):659-64. PubMed ID: 16291706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GH responsiveness in a large multinational cohort of SGA children with short stature (NESTEGG) is related to the exon 3 GHR polymorphism.
    Tauber M; Ester W; Auriol F; Molinas C; Fauvel J; Caliebe J; Nugent T; Fryklund L; Ranke MB; Savage MO; Clark AJ; Johnston LB; Hokken-Koelega AC;
    Clin Endocrinol (Oxf); 2007 Sep; 67(3):457-61. PubMed ID: 17555507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different relationships between the first 2 years on growth hormone treatment and the d3-growth hormone receptor polymorphism in short small-for-gestational-age (SGA) children.
    Dörr HG; Bettendorf M; Hauffa BP; Mehls O; Rohrer T; Stahnke N; Pfäffle R; Ranke MB;
    Clin Endocrinol (Oxf); 2011 Nov; 75(5):656-60. PubMed ID: 21623854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth Hormone (GH) receptor C.1319 G>T polymorphism, but not exon 3 retention or deletion is associated with better first-year growth response to GH therapy in patients with GH deficiency.
    Wan L; Chen WC; Tsai Y; Kao YT; Hsieh YY; Lee CC; Tsai CH; Chen CP; Tsai FJ
    Pediatr Res; 2007 Dec; 62(6):735-40. PubMed ID: 17957148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exon 3-deleted genotype of growth hormone receptor (GHRd3) positively influences IGF-1 increase at generation test in children with idiopathic short stature.
    Toyoshima MT; Castroneves LA; Costalonga EF; Mendonca BB; Arnhold IJ; Jorge AA
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):500-4. PubMed ID: 17555512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The interactive effect of GHR-exon 3 and -202 A/C IGFBP3 polymorphisms on rhGH responsiveness and treatment outcomes in patients with Turner syndrome.
    Braz AF; Costalonga EF; Montenegro LR; Trarbach EB; Antonini SR; Malaquias AC; Ramos ES; Mendonca BB; Arnhold IJ; Jorge AA
    J Clin Endocrinol Metab; 2012 Apr; 97(4):E671-7. PubMed ID: 22278433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The exon 3-deleted/full-length growth hormone receptor polymorphism and response to growth hormone therapy in growth hormone deficiency and Turner syndrome: a multicenter study.
    Baş F; Darendeliler F; Aycan Z; Çetinkaya E; Berberoğlu M; Sıklar Z; Öcal G; Timirci Ö; Çetinkaya S; Darcan Ş; Gökşen Şimşek D; Bideci A; Cinaz P; Böber E; Demir K; Bereket A; Turan S; Atabek ME; Tütüncüler F; Isbir T; Bozkurt N; Kabataş Eryılmaz S; Uzunhan O; Küçükemre Aydın B; Bundak R
    Horm Res Paediatr; 2012; 77(2):85-93. PubMed ID: 22456308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic predictors of long-term response to growth hormone (GH) therapy in children with GH deficiency and Turner syndrome: the influence of a SOCS2 polymorphism.
    Braz AF; Costalonga EF; Trarbach EB; Scalco RC; Malaquias AC; Guerra-Junior G; Antonini SR; Mendonca BB; Arnhold IJ; Jorge AA
    J Clin Endocrinol Metab; 2014 Sep; 99(9):E1808-13. PubMed ID: 24905066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MECHANISMS IN ENDOCRINOLOGY: Clinical and pharmacogenetic aspects of the growth hormone receptor polymorphism.
    Boguszewski CL; Barbosa EJL; Svensson PA; Johannsson G; Glad CAM
    Eur J Endocrinol; 2017 Dec; 177(6):R309-R321. PubMed ID: 28904008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GH receptor d3 polymorphism in Dutch patients with MPHD and IGHD born small or appropriate for gestational age.
    de Graaff LC; Meyer S; Els C; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2008 Jun; 68(6):930-4. PubMed ID: 18031312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between nocturnal growth hormone concentrations, serum IGF-I/IGFBP-3 levels, insulin sensitivity and GH receptor allelic variant in small for gestational age children.
    Mericq V; Román R; Iñiguez G; Angel B; Salazar T; Avila A; Perez-Bravo F; Cassorla F
    Horm Res; 2007; 68(3):132-8. PubMed ID: 17347571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The exon 3-deleted/full-length growth hormone receptor polymorphism did not influence growth response to growth hormone therapy over two years in prepubertal short children born at term with adequate weight and length for gestational age.
    Carrascosa A; Audí L; Fernández-Cancio M; Esteban C; Andaluz P; Vilaró E; Clemente M; Yeste D; Albisu MA; Gussinyé M
    J Clin Endocrinol Metab; 2008 Mar; 93(3):764-70. PubMed ID: 18160465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone pharmacogenetics: the interactive effect of a microsatellite in the IGF1 promoter region with the GHR-exon 3 and -202 A/C IGFBP3 variants on treatment outcomes of children with severe GH deficiency.
    Costalonga EF; Antonini SR; Guerra G; Coletta RR; Franca MM; Braz AF; Mendonca BB; Arnhold IJ; Jorge AA
    Pharmacogenomics J; 2012 Oct; 12(5):439-45. PubMed ID: 21468024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor I and growth responses during the first year of growth hormone treatment in KIGS patients with idiopathic growth hormone deficiency, acquired growth hormone deficiency, turner syndrome and born small for gestational age.
    Cutfield WS; Lundgren F
    Horm Res; 2009 Jan; 71 Suppl 1():39-45. PubMed ID: 19153504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.